Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon

Beta blockers ‘have no effect’ on heart attack patients

One researcher described the study's findings as "one of the most significant advances in heart attack treatment in decades.”

An attendee at AHA 2024 looking at educational displays on Lp(a) in the Novartis booth. Photo By Dave Fornell

Health systems use AI to target patients who may have elevated Lp(a) levels

"We can start helping people right now, and it would be meaningful if we can raise more awareness to reduce the burden of CVD," explained Katherine Wilemon, founder and CEO of the Family Heart Foundation. 

Thumbnail

Oral GLP-1 drug linked to weight loss in patients with and without diabetes—is FDA approval next?

Eli Lilly and Company is back with even more positive data on orforglipron, its oral GLP-1 receptor agonist. The company says it is "moving with urgency" toward gaining key regulatory approvals and getting the drug in the hands of patients.

radiology trends lungs imaging graphs

FDA clears new trial of first-in-class treatment for pulmonary arterial hypertension

The new drug, VTB-10, previously received the FDA's orphan drug designation in 2024.

Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, Chairman of the Board for the Family Heart Foundation, past president of the American Society for Preventive Cardiology, clinical affiliate professor of biomedical science at Florida Atlantic University, and chief medical officer of Flourish Research, explains why testing for familial hypercholesterolemia (FH) and elevated Lipoprotein(a) could be critical to identify more patients with elevated risk of cardiac events, but have their LDL well controlled.

Lipoprotein(a) tests could transform patient care—is it time for universal screening?

"Lp(a) represents the most important potential potential paradigm shift in cardiovascular disease prevention that we'll experience over the next five to 10 years," Seth Baum, MD, explained in a new interview.

Cardiac amyloidosis ATTR-CM drug promotion at the 2024 American Heart Association meeting.

High cost of cardiac amyloidosis drugs may limit access for low-income patients

"We cannot accept a system where only those with means can benefit from life-changing drugs. We are a wealthy nation that spends trillions on healthcare. We must ensure that income and wealth do not determine access," explained JACC Editor-in-Chief Harlan M. Krumholz, MD.

weight loss scale overweight obese lose weight pounds

Another win for Lilly: Oral GLP-1 drug linked to significant weight loss, other cardiovascular benefits

Tirzepatide and semaglutide are getting the attention now, but orforglipron could be the next go-to drug for patients hoping to lose weight and improve their heart health—no injections required.

pain pills opioids

Texas cardiologist to pay $1.2M for allegedly prescribing opioids to himself

The interventional cardiologist was accused of prescribing a variety of drugs to his family and friends, but then picking them up himself for his own personal use. This settlement officially resolves those allegations. 

Displaying 25 - 32 of 393
Design by Adaptive Theme